CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $181.14M, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
181.14MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.3980xvs all stocks
52-Week Change
-25.14%vs all stocks
Market Capitalization
181.14MUSDvs all stocks (USD)
Enterprise Value
53.95MUSDvs all stocks (USD)
Forward P/E
-2.43xvs Biotechnology peers
Price to Book (MRQ)
1.33xvs Biotechnology peers
Enterprise to EBITDA
-0.6560xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-40.40%vs Biotechnology peers
Return on Equity (TTM)
-80.65%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-82.30MUSDvs all stocks (USD)
Net Income (TTM)
-80.89MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-70.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-41.16MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-100.85MUSDvs all stocks (USD)
Pre-tax Income
-101.69MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-101.69MUSDFY2025 · Dec 31, 2025EBIT
-100.09MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-96.21MUSDFY2025 · Dec 31, 2025Research & Development
77.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
23.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.60MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-101.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-88.73MUSDFY2025 · Dec 31, 2025Free Cash Flow
-88.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
16.44MUSDFY2025 · Dec 31, 2025Interest Paid
1.26MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-101.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
706.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.58MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
272.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.60MUSDFY2025 · Dec 31, 2025Capital Expenditures
-212.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-51.59MUSDFY2025 · Dec 31, 2025Sale of Investments
134.39MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
82.59MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.36MUSDFY2025 · Dec 31, 2025Other Financing Charges
1.69MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
324.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
138.22MSharesUpdated Sep 26, 2026Float Shares
94.73MSharesUpdated Sep 26, 2026Shares Short
6.27MSharesUpdated Sep 26, 2026Short Ratio
9.03daysvs all stocks
Short % of Shares Outstanding
5.03%vs all stocks
% Held by Insiders
0.89%vs all stocks
% Held by Institutions
84.62%vs all stocks
Total Cash (MRQ)
138.23MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.00USDUpdated Sep 26, 2026Total Debt (MRQ)
11.04MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0810xvs Biotechnology peers
Current Ratio (MRQ)
9.71xvs Biotechnology peers
Book Value per Share (MRQ)
0.9850USDUpdated Sep 26, 2026Total Assets
59.05MUSDvs all stocks (USD)
Total Current Assets
50.73MUSDFY2025 · Dec 31, 2025Total Liabilities
33.06MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.32MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.51MUSDFY2025 · Dec 31, 2025Total Current Liabilities
24.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
16.37MUSDFY2025 · Dec 31, 2025Other Short-term Investments
28.42MUSDFY2025 · Dec 31, 2025Accounts Payable
4.91MUSDFY2025 · Dec 31, 2025Short-term Debt
5.22MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.32MUSDFY2025 · Dec 31, 2025Long-term Debt
4.53MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
3.98MUSDFY2025 · Dec 31, 2025Common Stock (Book)
54.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-722.82MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
25.98MUSDvs all stocks (USD)
52-Week Low
1.05USDUpdated Sep 26, 202652-Week High
2.66USDUpdated Sep 26, 202652-Week Change
-25.14%vs all stocks
Beta
0.3980xvs all stocks
50-Day MA
1.92USDUpdated Sep 26, 2026200-Day MA
1.84USDUpdated Sep 26, 2026Avg 10-Day Volume
1.32MSharesUpdated Sep 26, 2026Avg 30-Day Volume
890.88KSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-1.15USDUpdated Sep 26, 2026Other Income / Expense
-3.21MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $181.14M, lower than 95% of all stocks globallySignificant
Market cap (USD): 181,142,866Global P5: 275,556,405.438
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Organogenesis Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
NervGen Pharma Corp.
Tier 1ProductionApproval-Gated PipelineRule
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ADC Therapeutics S.A.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Eos Energy Enterprises Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Defi Technologies Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown